Skip to Content
Simtra BioPharma Solutions Home

Specialized Containment

Ensuring Safety and
Regulatory Compliance

For products requiring complex handling, such as cytotoxics and highly potent compounds, we use open or closed RABS (restricted access barrier system) technologies, as appropriate. These manufacturing environments are designed to provide containment during filling operations and to ensure that we are compliant with all safety and regulatory requirements.

Handling Highly Potent Compounds

For extremely sensitive highly potent compounds, we maintain a closed RABS (cRABS) manufacturing environment and isolators, which help to preserve the integrity of these drug molecules, maintain product sterility and ensure the safety of the line operators. The cRABS manufacturing areas have independent air supply and waste disposal systems, including 100% waste collection. Operators in these areas are highly trained and experienced, with expertise in carcinogenic, mutagenic and reprotoxic products. They use special equipment, observe robust standard operating procedures and conduct rigorous risk assessments.

Facility Certification

Our Halle/Westfalen and Bloomington facilities are cGMP compliant, have environmental, health and safety certifications according to ISO 14001 and 45001, and meet FDA (United States), PDMA (Japan) and EMA (European Union) regulatory standards. In addition, the Halle/Westfalen facility is ISO 50001-certified and holds a SafeBridge-certificate for the manufacture of sterile potent pharmaceutical final dosage forms.

Contact Us

Learn more about our specialized containment capabilities.

Related Resources

Manufacturing of Cytotoxic and Non-Cytotoxic Drugs in a Multiproduct Facility

A CDMO with expertise in handling multiple drug types in one facility can implement an effective risk-based approach to avoiding cross-contamination.

Solid State Hydrogen Deuterium Exchange to Study Antibody Drug Conjugate Stability

Scientists at Simtra and Purdue University have investigated the ability of solid state HDX-MS as a tool to predict the stability of a proprietary, IgG-based ADC.

Bringing Your Sterile Injectable Product to Market: Considerations for Collaborating with a Fill Finish CDMO

Considerations include RFP timing, specificity of the RFP and the proposal, close candidate evaluation and a collaborative approach on scope and timeline.